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Background: Patients with chronic obstructive pulmonary disease (COPD) are at increased 
risk of developing lower extremity peripheral artery disease (PAD) and suffering PAD- 
related morbidity and mortality. However, the effect and burden of COPD on patients with 
PAD is less well defined. This post hoc analysis from EUCLID aimed to analyze the risk of 
major adverse cardiovascular events (MACE) and major adverse limb events (MALE) in 
patients with PAD and concomitant COPD compared with those without COPD, and to 
describe the adverse events specific to patients with COPD.
Methods: EUCLID randomized 13,885 patients with symptomatic PAD to monotherapy 
with either ticagrelor or clopidogrel for the prevention of MACE. In this analysis, MACE, 
MALE, mortality, and adverse events were compared between groups with and without 
COPD using unadjusted and adjusted Cox proportional hazards model.
Results: Of the 13,883 patients with COPD status available at baseline, 11% (n=1538) had 
COPD. Patients with COPD had a higher risk of MACE (6.02 vs 4.29 events/100 patient- 
years; p<0.001) due to a significantly higher risk of myocardial infarction (MI) (3.55 vs 1.85 
events/100 patient-years; p<0.001) when compared with patients without COPD. These risks 
persisted after adjustment (MACE: adjusted hazard ratio (aHR) 1.30, 95% confidence 
interval [CI] 1.11–1.52; p<0.001; MI: aHR 1.45, 95% CI 1.18–1.77; p<0.001). However, 
patients with COPD did not have an increased risk of MALE or major bleeding. Patients with 
COPD were more frequently hospitalized for dyspnea and pneumonia (2.66 vs 0.9 events/ 
100 patient-years; aHR 2.77, 95% CI 2.12–3.63; p<0.001) and more frequently discontinued 
study drug prematurely (19.36 vs 12.54 events/100 patient-years; p<0.001; aHR 1.34, 95% 
CI 1.22–1.47; p<0.001).
Conclusion: In patients with comorbid PAD and COPD, the risks of MACE, respiratory- 
related adverse events, and premature study drug discontinuation were higher when com-
pared with patients without COPD.
Registration: ClinicalTrials.gov: NCT01732822.
Keywords: peripheral artery disease, chronic obstructive pulmonary disease, major adverse 
cardiovascular events
Chronic obstructive pulmonary disease (COPD) is a leading cause of death 
worldwide.1 Due to shared risk factors, particularly cigarette smoking, patients 
with COPD are at increased risk of developing cardiovascular disease.2–4 In 
patients with known COPD, peripheral artery disease (PAD) is more prevalent 
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than in age-matched patients without COPD, affecting 
8.8% of a cohort of patients with COPD with a mean 
age of 65 compared with 1.8% of those without COPD.5 
In prospective studies of patients with COPD, a diagnosis 
of PAD was associated with lower exercise tolerance, 
a higher incidence of major adverse cardiovascular events 
(MACE), and higher all-cause mortality.6–8
In contrast, the prevalence of COPD among patients 
with PAD, as well as the added risk of MACE, major 
adverse limb events (MALE), and respiratory events asso-
ciated with COPD, are less well defined. Understanding 
the additional burden associated with COPD concomitant 
with PAD has both clinical and research implications, 
including understanding the increased cardiovascular and 
limb risk, as well as adherence to medications, that may 
improve trial planning and patient management in this 
population. The EUCLID (Examining Use of Ticagrelor 
in Peripheral Artery Disease) study was a large cardiovas-
cular outcomes trial in patients with symptomatic PAD 
that compared monotherapy between ticagrelor and clopi-
dogrel, and it affords an opportunity to study the natural 
history of patients with PAD.9 Of note, ticagrelor carries 
the unique side effect of dyspnea, which may dispropor-
tionately affect medication adherence, and therefore clin-
ical outcomes, among this cohort of patients with COPD.9 
The primary aim of this analysis was to compare the 
occurrence of MACE and MALE in patients with PAD 
with and without concomitant COPD. The secondary aims 
were to compare all-cause mortality, Thrombolysis in 
Myocardial Infarction (TIMI) major bleeding, serious 
adverse events (all-cause and respiratory-related hospitali-
zations, premature study drug discontinuation), and non- 
serious adverse events (dyspnea, pneumonia, and 
malignancy) between groups in order to characterize the 
added burden of hospitalizations and adverse events asso-
ciated with COPD. We hypothesized that patients with 
PAD and COPD have higher rates of MACE and MALE, 
are hospitalized for respiratory causes more often, prema-
turely discontinue study drug more frequently, and have 
dyspnea, pneumonia, and malignancy more often.
Methods
Study Design and Participants
Details of the EUCLID study design have been previously 
published.9,10 In brief, EUCLID was a multi-center, dou-
ble-blind, active-comparator randomized controlled trial of 
13,885 patients aged 50 years or older with lower 
extremity PAD comparing monotherapy with either tica-
grelor (90 mg twice daily) or clopidogrel (75 mg once 
daily) in a 1:1 fashion. Enrollment criteria included either 
a history of lower extremity revascularization or an abnor-
mal ankle-brachial index (ABI) ≤0.80. The presence or 
absence of COPD was assessed at the enrolling study 
visit on the basis of the documented medical history. For 
patients with a documented medical history of COPD, 
further data regarding the patients’ supplemental oxygen 
requirement and previous COPD-related hospitalizations 
was obtained (Figure 1). Information on COPD severity 
(i.e., Global Initiative for Obstructive Lung Disease 
[GOLD] criteria and pulmonary function testing) was not 
ascertained at any point in the study. The study was 
approved by all local Ethics Committees and Institutional 
Review Boards (Appendix Table I).
Outcomes
The primary efficacy and safety endpoints in EUCLID 
were MACE (a composite of cardiovascular death, myo-
cardial infarction, or ischemic stroke) and major bleeding 
according to TIMI criteria. For the present analysis, our 
primary efficacy outcomes were MACE and MALE (a 
composite of hospitalization for acute limb ischemia or 
major lower extremity amputation). Secondary endpoints 
of interest were all-cause mortality, serious adverse events 
(all-cause hospitalization, hospitalization for dyspnea or 
pneumonia, and premature study drug discontinuation), 
and non-serious adverse events of special interest (dys-
pnea, pneumonia, malignancy, and any respiratory-related 
adverse event). Serious adverse events were defined as 
adverse events resulting in death or hospitalization. Each 
endpoint and adverse event was collected via the case 
report form at every clinic visit. The efficacy and safety 
endpoints of myocardial infarction (MI), cardiovascular 
death, stroke, acute limb ischemia, and bleeding were 
adjudicated according to the EUCLID Clinical Endpoints 
Classification Charter by board-certified cardiologists or 
neurologists, depending on the event type. Adverse events 
were systematically collected in all participants in the 
EUCLID trial. Those adverse events that were serious, 
including hospitalizations and events that led to study 
drug discontinuation, were reviewed by the Duke 
Clinical Research Institute Safety Surveillance Group, 
and these adverse events were cross-referenced with the 
Clinical Endpoints Classification database to ensure that 
clinical endpoints were not double counted.
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Figure 1 Inclusion criteria for EUCLID trial. This figure highlights the inclusion criteria of patients for both the EUCLID trial and this COPD-focused post hoc analysis of the 
EUCLID trial.
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Statistical Analysis
The analytic cohort included all patients randomized in 
EUCLID who received at least one dose of study drug and 
had information on COPD status at baseline (n=13,883). 
For baseline characteristics, continuous variables were 
reported as medians with associated 25th and 75th percen-
tiles and were compared between patients with and with-
out COPD using the Wilcoxon rank sum test. Categorical 
variables were reported as counts with percentages and 
were assessed using the chi-square test.
The efficacy and safety outcomes (MACE, MALE, 
bleeding, and all-cause mortality) and serious adverse 
events (all-cause and respiratory-related hospitalizations 
and premature study drug discontinuation) were evaluated 
as time-to-event outcomes. Incidence rates were calculated 
as the number of events per 100 patient-years of follow- 
up. The unique number of patients who experienced non- 
serious adverse events and the mean and median number 
of adverse events per patient are reported by COPD status.
The relationships between baseline COPD and effi-
cacy and safety outcomes and serious adverse events 
were examined using unadjusted and adjusted Cox pro-
portional hazards models. The models were adjusted for 
randomized treatment and differing sets of baseline clin-
ical characteristics including age, sex, weight, body mass 
index, tobacco use, prior medical history, medications, 
limb symptoms at study entry, and prior revasculariza-
tions/amputations (Appendix Table II). The proportional 
hazards assumption was assessed using weighted 
Schoenfield residuals and no major violations were 
found. The linearity assumption for continuous adjust-
ment variables was also examined, and natural cubic 
splines were used when necessary. Hazard ratios (HR) 
with 95% confidence intervals (CI) comparing patients 
with COPD with those without COPD at baseline and the 
associated p-values are presented. The analysis of non- 
serious adverse events did not undergo adjustment.
To evaluate the interaction between treatment arm and 
COPD, the unadjusted Cox proportional hazards models 
from above were additionally fit with randomized treat-
ment and the interaction between treatment and COPD 
status. HRs with 95% CIs comparing ticagrelor with clo-
pidogrel for those with and without COPD are presented 
with interaction p-values.
All analyses were performed by the Duke Clinical 
Research Institute (Durham, NC) using SAS version 9.4 
(SAS Institute, Inc. Cary, NC).
Results
Study Population and Clinical 
Characteristics
Of the 13,883 patients enrolled in EUCLID who received 
at least one dose of study drug and had COPD status 
available, a total of 1538 patients (11%) had COPD at 
baseline (Table 1). Patients with COPD were similarly 
distributed between the ticagrelor (50.9% [n=783]) and 
clopidogrel (49.1% [n=755]) treatment groups. Of those 
with COPD, 5.7% (n=87) required daily oxygen therapy 
and 12.4% (n=191) had a COPD hospitalization in the year 
prior to enrollment. Patients with baseline COPD were 
older than those without COPD (median 67 vs 66 years, 
p<0.001), weighed more (median 78 kg vs 76kg, p=0.012), 
and were more likely to be current or former smokers 
(92.5% vs 76.6%, p<0.001). Patients with COPD more 
frequently had a history of transient ischemic attack 
(TIA) (5.3% vs 3.4%), carotid artery disease (26.6% vs 
18.3%), coronary artery disease (CAD) (35.6% vs 28.2%), 
MI (21.4% vs 17.8%), hypertension (83.4% vs 77.6%), 
hyperlipidemia (82.3% vs 74.6%), and prior malignancy 
(12.9% vs 7.3%) compared with patients without COPD 
(all p-values <0.001). Interestingly, patients with PAD and 
COPD had lower rates of diabetes when compared with 
those without COPD (32.6% vs 39.2%, p<0.001).
Patients with PAD and COPD had a higher rate of 
statin (77.5% vs 72.8%, p<0.001) and antiplatelet use 
prior to study entry, specifically aspirin (71.3% vs 
66.2%, p<0.001) and clopidogrel (39.4% vs 31.3%, 
p<0.001). Patients with PAD and COPD had more fre-
quently undergone a previous lower extremity revascular-
ization (63.6% vs 55.9%, p<0.001) and experienced more 
severe limb symptoms (severe claudication and ischemic 
rest pain) at study entry when compared with the remain-
ing study population.
Unadjusted Outcomes
Efficacy and Safety Outcomes
The risk of occurrence of the primary composite end-
point (cardiovascular death, MI, or ischemic stroke) is 
shown in Figure 2 and Appendix Figure I. There was 
a significantly higher risk of MACE in patients with 
PAD and COPD compared with those without COPD 
(6.02 vs 4.29 events/100 patient-years, p<0.001). This 
was primarily driven by a higher occurrence of MI (3.55 
vs 1.85 events/100 patient-years, p<0.001), with no sta-
tistically significant difference in the number of 
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Table 1 Baseline Clinical Characteristics by COPD at Baseline
COPD (N=1538) No COPD (N=12,345) P-value
Age, (median, IQR), yrs 67, 62–73 66, 60–72 <0.001
Female, no. (%) 438 (28.5%) 3450 (27.9%) 0.661
Weight, (median, IQR), kg 78, 66–91 76, 66–88 0.012
BMI (mean, IQR) 27, 24–31 27, 24–30 0.309
Chronic lung disease characteristics, no. (%)
Required daily, long-term oxygen therapy 87 (5.7%)
Hospitalization in the last year 191 (12.4%)
Inclusion criteria for randomization, no. (%) <0.001
Previous revascularization 978 (63.6%) 6896 (55.9%)
ABI criteria 560 (36.4%) 5449 (44.1%)
ABI values based on inclusion criteria, mean (SD)
Previous revascularization 0.79 (0.22) 0.78 (0.23) 0.033
ABI criteria 0.63 (0.13) 0.63 (0.15) 0.117
Limb symptoms at baseline, no. (%) <0.001
Asymptomatic 239 (15.5%) 2362 (19.1%)
Mild or moderate claudication 762 (49.5%) 6648 (53.9%)
Severe claudication 470 (30.6%) 2758 (22.3%)
Ischemic rest pain 49 (3.2%) 329 (2.7%)
Minor tissue loss 12 (0.8%) 195 (1.6%)
Major tissue loss 6 (0.4%) 52 (0.4%)
Major amputation above the ankle, no. (%) 28 (1.8%) 311 (2.5%) 0.092
Minor amputation, no. (%) 32 (2.1%) 573 (4.7%) <0.001
Tobacco use, no. (%) <0.001
Current 665 (43.6%) 3624 (29.5%)
Former 746 (48.9%) 5784 (47.1%)
Never 115 (7.5%) 2869 (23.4%)
Prior medical history, no. (%)
Stroke 128 (8.3%) 1015 (8.2%) 0.892
Transient ischemic attack 82 (5.3%) 425 (3.4%) <0.001
Coronary artery disease 548 (35.6%) 3484 (28.2%) <0.001
Myocardial infarction 329 (21.4%) 2193 (17.8%) <0.001
Carotid stenosis or carotid revascularization 394 (26.6%) 2133 (18.3%) <0.001
Diabetes mellitus type I or II 502 (32.6%) 4843 (39.2%) <0.001
Hypertension 1282 (83.4%) 9575 (77.6%) <0.001
Hyperlipidemia 1266 (82.3%) 9214 (74.6%) <0.001
History of cancer 198 (12.9%) 900 (7.3%) <0.001
Medications before randomization, no. (%)
Aspirin 1097 (71.3%) 8174 (66.2%) <0.001
Clopidogrel 606 (39.4%) 3867 (31.3%) <0.001
Statin 1192 (77.5%) 8989 (72.8%) <0.001
ACE inhibitor 632 (41.1%) 5003 (40.5%) 0.670
Angiotensin-receptor blocker 415 (27.0%) 3073 (24.9%) 0.075
Cilostazol 183 (11.9%) 1912 (15.5%) <0.001
(Continued)
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cardiovascular deaths (2.35 vs 2.01 events/100 patient- 
years, p=0.059) or ischemic strokes (0.85 vs 0.89 
events/100 patient-years, p=0.691). Specifically, 50.0% 
(n=65) of the MIs experienced by patients with conco-
mitant PAD and COPD were type 1 and 43.8% (n=57) 
were type 2, compared with 61.5% (n=340) type 1 and 
32.4% (n=179) type 2 MIs in patients without COPD. 
After excluding type 2 MI from the endpoint definitions, 
the higher risk of MACE in patients with PAD and 
COPD compared with those without COPD persisted 
(4.78 vs 3.79 events/100 patient-years, p=0.004), as 
did risk of MI (2.05 vs 1.28 events/100 patient-years, 
p<0.001). The occurrence of MALE was 1.10 events per 
100 patient-years in patients with COPD and 1.19 
events per 100 patient-years in patients without COPD 
(p=0.54). Patients with COPD did not have any increase 
in major bleeding (0.90 vs 0.74 events/100 patient- 
years, p=0.34), but did have higher all-cause mortality 
(5.01 vs 3.46 events/100 patient-years, p<0.001) com-
pared with those without COPD.
Table 1 (Continued). 
COPD (N=1538) No COPD (N=12,345) P-value
Randomized treatment assignment, no. (%) 0.405
Clopidogrel 75 mg once daily 755 (49.1%) 6199 (50.2%)
Ticagrelor 90 mg twice daily 783 (50.9%) 6146 (49.8%)
Abbreviations: ABI, ankle-brachial index; ACE, angiotensin-converting enzyme; BMI, body mass index; COPD, chronic obstructive pulmonary disease; SD, standard 
deviation.
Figure 2 Kaplan–Meier plot of primary endpoint by history of COPD. The rate of occurrence of the primary endpoint (composite of cardiovascular death, myocardial 
infarction and ischemic stroke) is greater in patients with a history of COPD, compared to PAD patients without baseline COPD.
submit your manuscript | www.dovepress.com                                                                                                                                                                                                                    
DovePress                                                                                            
International Journal of Chronic Obstructive Pulmonary Disease 2021:16 846


















































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Serious Adverse Events
All-cause hospitalizations were significantly higher among 
patients with COPD when compared with patients without 
COPD (33.30 vs 21.53 events/100 patient-years, p<0.001). 
Specifically, patients with PAD and COPD were hospita-
lized for dyspnea and pneumonia more frequently when 
compared with patients without COPD (2.66 vs 0.90 
events/100 patient-years, p<0.001). Patients with COPD 
had a significantly greater rate of premature study drug 
discontinuation (19.36 vs 12.54 events/100 patient-years, 
p<0.001) than those without COPD. Table 2 further spe-
cifies serious adverse events by history of COPD.
Non-Serious Adverse Events
Table 3 details the non-serious adverse events by history 
of COPD. The frequency of all adverse events and respira-
tory-related adverse events was higher in patients with 
PAD and COPD compared with those without COPD. 
Among patients with baseline COPD, more patients 
experienced at least one respiratory-related adverse event 
than patients without baseline COPD (22.8% vs 8.9%). 
However, the number of respiratory-related adverse events 
experienced per patient was similar between the two 
groups (mean 1.4 vs 1.2 adverse events per patient). 
When examining specific adverse events of interest, 
patients with PAD and COPD were more likely to report 
dyspnea (14.6% vs 7.1%), pneumonia (6.7% vs 2.9%), and 
malignancy (6.1% vs 4.3%) when compared with patients 
without baseline COPD. Patients with PAD and COPD 
were also more likely to require hospitalization for 
a serious adverse event (35.2% vs 22.6%) than those with-
out COPD.
Adjusted Outcomes
Efficacy and Safety Outcomes
Figure 3 details the risk of occurrence of the efficacy and 
safety endpoints after adjustment for baseline characteris-
tics. The adjusted hazard ratio (aHR) for MACE was 1.30 
(95% CI 1.11–1.52, p<0.001) and for MI was 1.45 (95% 
CI 1.18–1.77, p<0.001). After excluding type 2 MI, the 
aHR for MACE was 1.21 (95% CI 1.02–1.43, p=0.030) 
and for MI was 1.26 (95% CI 0.97–1.62, p=0.083). 
Patients with PAD and COPD did not have a higher risk 
of adverse limb events (aHR 0.98, 95% CI 0.71–1.37, 
p=0.92) than those without COPD. Patients with PAD 
and COPD had a higher risk of all-cause mortality (aHR 
1.50, 95% CI: 1.27–1.76, p<0.001) compared with those 
without COPD. However, there was no increased risk of 
bleeding observed in patients with PAD and COPD when 
compared with patients without baseline COPD (aHR 





Hospitalization for any SAE
Unique N 538 (35.2%) 2780 (22.6%)
Mean (SD) PP* 2.0 (1.5) 1.6 (1.2)
Hospitalization for any 
respiratory SAE
Unique N 144 (9.4%) 211 (1.7%)
Mean (SD) PP* 1.4 (0.8) 1.2 (0.6)
Hospitalization for dyspnea
Unique N 6 (0.4%) 9 (0.1%)
Mean (SD) PP* 1.0 (0.0) 1.2 (0.4)
Hospitalization for 
pneumonia
Unique N 75 (4.9%) 230 (1.9%)
Mean (SD) PP* 1.1 (0.4) 1.0 (0.2)
Hospitalization for 
malignancy
Unique N 62 (4.1%) 385 (3.1%)
Mean (SD) PP* 1.0 (0.1) 1.1 (0.2)
Note: *Per patient with at least 1 adverse event of that type. 
Abbreviations: COPD, chronic obstructive pulmonary disease; SAE, serious 
adverse event; SD, standard deviation.






Unique N 868 (56.7%) 5031 (40.9%)
Mean (SD) PP* 2.5 (2.2) 2.1 (2.2)
Respiratory† adverse 
event
Unique N 349 (22.8%) 1090 (8.9%)
Mean (SD) PP* 1.4 (0.8) 1.2 (0.5)
Dyspnea
Unique N 224 (14.6%) 870 (7.1%)
Mean (SD) PP* 1.2 (0.5) 1.2 (0.5)
Pneumonia
Unique N 103 (6.7%) 352 (2.9%)
Mean (SD) PP* 1.2 (0.5) 1.1 (0.4)
Malignancy
Unique N 93 (6.1%) 527 (4.3%)
Mean (SD) PP* 1.2 (0.5) 1.1 (0.3)
Notes: *Per patient with at least 1 adverse event of that type. †Respiratory defined 
by the respiratory, thoracic and mediastinal body system.
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1.04, 95% CI 0.69–1.56, p=0.866), and there was no 
interaction between COPD status and response to ticagre-
lor for any clinical outcome.
Serious Adverse Events
Patients with COPD were at higher risk of all-cause hos-
pitalization (aHR 1.41, 95% CI 1.31–1.53, p<0.001) after 
adjustment, and specifically at risk of hospitalization for 
dyspnea and pneumonia (aHR 2.77, 95% CI 2.12–3.63, 
p<0.001) compared with those without COPD. Patients 
with PAD and COPD were more likely to prematurely 
discontinue their assigned study drug when compared 
with patients without baseline COPD, regardless of 
whether it was ticagrelor or clopidogrel (19.36 vs 12.54 
discontinuations/100 patient-years; aHR 1.34, 95% CI 
1.22–1.47, p<0.001). In patients with PAD both with and 
without COPD, there was an increased risk of premature 
study drug discontinuation with ticagrelor compared with 
clopidogrel (PAD with COPD: aHR 1.22, 95% CI 
1.04–1.44; PAD without COPD: aHR 1.21, 95% CI 
1.13–1.30). However, there was no significant difference 
in the hazard ratios comparing ticagrelor with clopidogrel 
discontinuation between patients with and without COPD 
(interaction p=0.913).
Discussion
We evaluated the past medical history, clinical outcomes 
and adverse events in patients with concomitant PAD and 
COPD using data from the EUCLID study, yielding four 
major findings. First, patients with PAD and COPD had 
more comorbidities at baseline and had more severe PAD 
at the time of study entry than those without COPD. 
Second, patients with PAD and COPD had a higher risk 
of MACE (primarily driven by a significantly higher rate 
of MI) and a higher risk of all-cause mortality and all- 
cause hospitalization, findings that persisted after adjust-
ment for baseline characteristics. Third, patients with PAD 
and COPD did not have a higher risk of MALE compared 
Figure 3 Association between baseline COPD and clinical outcomes. This forest plot highlights the primary efficacy outcomes (MACE and MALE), secondary endpoints of 
interest (all-cause mortality), safety endpoints (TIMI major bleed), and serious adverse events (all-cause hospitalizations, hospitalization for dyspnea or pneumonia, 
premature study drug discontinuation).
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with patients with PAD without COPD, despite more 
severe PAD at baseline. Finally, patients with PAD and 
COPD more frequently experienced respiratory-related 
serious adverse events, including respiratory-related hos-
pitalizations, and were more likely to discontinue the study 
drug prematurely, regardless of whether it was ticagrelor 
or clopidogrel.
The few prior studies of patients with concomitant 
PAD and COPD have focused on mortality, which they 
reported was higher in this population, consistent with our 
data.11,12 Our analysis adds depth and nuance to these 
findings, showing that the increase in all-cause mortality 
is not due to cardiovascular mortality, while patients with 
COPD are also at significantly greater risk of other clini-
cally-important events. Patients with COPD in addition to 
PAD carry an increased risk of MACE driven by signifi-
cantly higher risks of MI, specifically type 2 MI, as well as 
increased risks of all-cause and respiratory-related hospi-
talizations. Patients with PAD who were hospitalized for 
acute pulmonary events have been shown to be at 
increased risk of MACE following the hospitalization, 
and the same has been observed in patients both with 
and without COPD.13–16 This is hypothesized to be due 
to the inflammatory state associated with pulmonary 
hospitalizations.13,15,16 It is possible that the increased 
risk of MI we observed in EUCLID participants with 
PAD and COPD is attributable to the more frequent 
respiratory-related adverse events experienced by the 
patients with PAD and baseline COPD. Furthermore, 
these pulmonary exacerbations may lead to hypoxia, creat-
ing an imbalance between myocardial oxygen demand and 
delivery and an increased frequency of type 2 MI seen in 
patients with concomitant PAD and COPD when com-
pared with patients without COPD.17 Although a higher 
frequency of type 2 MI is expected in patients with COPD, 
our data shows persistence of the higher risk of MACE in 
patients with concomitant PAD and COPD even after 
exclusion of type 2 MI from the primary endpoints, sug-
gesting that type 2 MI may not be the sole cause of 
increased mortality in this population. Interestingly, while 
MALE is also associated with pro-inflammatory states 
such as those that might be experienced during COPD 
exacerbations, there was no increased risk for MALE in 
patients with COPD.
This study provides new information on adverse events 
unique to patients with concomitant PAD and COPD. One 
noteworthy observation was an increased rate of premature 
study drug discontinuation in patients with PAD and 
COPD, with a higher risk of discontinuing ticagrelor com-
pared with clopidogrel in patients both with and without 
COPD. Ticagrelor carries the unique side effect of dys-
pnea, which may be particularly problematic for patients 
with COPD.9 In a meta-analysis of four randomized clin-
ical trials of ticagrelor, including EUCLID, premature 
ticagrelor discontinuation was seen in 25% of patients, 
and the highest risk of discontinuation was among patients 
who experienced dyspnea, a more common adverse event 
in patients with PAD and COPD compared with those 
without COPD.18 Ticagrelor-related dyspnea may com-
pound COPD-related dyspnea, complicating clinicians’ 
efforts to monitor patients with COPD for cardiac and 
pulmonary dysfunction.
While establishing worse clinical outcomes and 
a higher rate of adverse events for patients with concomi-
tant PAD and COPD, these findings also demonstrate the 
need for further research in this area. For instance, given 
the association between pulmonary hospitalizations and 
cardiovascular events, as well as the possibility of undiag-
nosed COPD among patients with PAD (given the over-
lapping risk factors), evaluation of enhanced monitoring 
strategies for cardiovascular events following pulmonary 
hospitalizations in patients with PAD should be consid-
ered. While the higher risk of MACE within this popula-
tion was driven solely by a significantly higher risk of MI, 
there is a dearth of evidence about the causes of non- 
cardiovascular death within this population. Additionally, 
further clarification is needed regarding the causes of pre-
mature study drug discontinuation, which may be attribu-
table to dyspnea or to decreased medication adherence 
associated with polypharmacy, hospitalizations, and 
increasing COPD symptoms in this population.19,20
There were limitations to this analysis. First, this was 
a post hoc analysis of a subgroup of patients that repre-
sented 5% of the overall study population. While this ana-
lysis focused only on patients with symptomatic PAD, 
COPD is more prevalent among patients with asymptomatic 
PAD, a group not included in this study.7,12 Second, discrete 
data on COPD severity (i.e., GOLD criteria, pulmonary 
function testing results, medications for COPD) were not 
ascertained at any point in the study, thereby making it 
difficult to correlate severity of baseline COPD with clinical 
outcomes. We relied on investigator reported history of 
COPD rather than any formal testing at time of enrollment. 
As a result, we may have failed to capture undiagnosed or 
less severe cases of COPD in the PAD alone group, as well 
as overreported cases of COPD in the COPD and PAD 
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group due to misclassification of other lung diseases such as 
asthma.21 Additionally, other comorbid chronic conditions 
in patients with COPD, such as heart failure, a highly 
possible alternative diagnosis in the EUCLID cohort, may 
be misdiagnosed as a COPD exacerbation.22 This may 
provide a falsely elevated rate of respiratory-related adverse 
events. Third, we were not able to ascertain whether the rate 
of ticagrelor discontinuation among patients with PAD and 
COPD for the reason of dyspnea was higher than in patients 
without COPD. Therefore, it is unclear if the decreased 
pulmonary reserve in patients with COPD was driving the 
increased risk of premature study drug discontinuation 
within that subgroup.
Conclusions
In patients with PAD and baseline COPD, the risk of major 
adverse cardiovascular events, all-cause mortality, all-cause 
hospitalizations, and respiratory-related adverse events was 
higher when compared with patients with PAD without 
COPD. Surprisingly, the rate of major adverse limb events 
was similar between patients with PAD with and without 
COPD. Patients with COPD were also more likely to dis-
continue study medication (either ticagrelor or clopidogrel) 
when compared with patients without COPD; however, after 
adjustment, the rate of discontinuation of ticagrelor was 
similar in patients with and without COPD. The results 
from this study suggest that the increased risk of multiple 
respiratory- and non-respiratory-related clinical events 
among patients with both COPD and PAD warrant increased 
efforts to investigate and prevent cardiovascular and respira-
tory events in this population.
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